Plasma Heat Shock Protein 90 Alpha: A Valuable Predictor of Early Chemotherapy Effectiveness in Advanced Non-Small-Cell Lung Cancer

Bo Zhong; Juxin Shen; Chunyi Zhang; Guozhong Zhou; Yuefang Yu; E Qin; Jixian Tang; Dongping Wu; Xiaochao Liang

doi:10.12659/MSM.924778

09 January 2021: Clinical Research

Plasma Heat Shock Protein 90 Alpha: A Valuable Predictor of Early Chemotherapy Effectiveness in Advanced Non-Small-Cell Lung Cancer

Bo Zhong ^1ACE , Juxin Shen ^1AEG* , Chunyi Zhang ^1BDE , Guozhong Zhou ^2BE , Yuefang Yu ^1DE , E Qin ^1BE , Jixian Tang ^1DE , Dongping Wu ^3DE , Xiaochao Liang ^1BE

DOI: 10.12659/MSM.924778

Med Sci Monit 2021; 27:e924778

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

View HTML version

Table 3 Tumor lesion diameter at different times before and after chemotherapy.

Variable	Before chemotherapy	Two cycles of chemotherapy	Four cycles of chemotherapy	P value
Longest diameter of tumor lesions	38.28 (29.02, 58.77)	32.36 (24.51, 46.43)	29 (22.32, 42.25)

Back to the Article

Plasma Heat Shock Protein 90 Alpha: A Valuable Predictor of Early Chemotherapy Effectiveness in Advanced Non-Small-Cell Lung Cancer

Your Privacy